Palatin Technologies, Inc. — FY2026 Form 10-K
Reporting period: Fiscal year ended June 30, 2026; comparisons are with the year ended June 30, 2025. Palatin is a development-stage biopharmaceutical company focused principally on melanocortin receptor agonists for obesity and rare MC4R-pathway disorders. It has no product sales; reported revenue comes from licensing and collaboration arrangements.
Financial results and liquidity
| Metric | FY2026 | FY2025 |
|---|---|---|
| Collaboration and license revenue | $13.19 million | $0 |
| Research and development expense | $12.37 million | $14.90 million |
| General and administrative expense | $9.48 million | $7.81 million |
| Loss from operations | $8.67 million | $17.46 million |
| Net loss | $8.38 million | $17.31 million |
| Net cash used in operating activities | $13.53 million | $21.31 million |
| Cash and cash equivalents at year-end | $7.49 million | $2.56 million |
- FY2026 revenue comprised $9.43 million under the Boehringer Ingelheim (BI) agreement and $3.75 million under the Altanispac sublicense. The Altanispac consideration was non-cash debt cancellation.
- Year-end current assets were $8.16 million and current liabilities were $1.77 million, for working capital of approximately $6.39 million. Total liabilities were $1.84 million; disclosed lease liabilities totaled $223,679. The filing does not identify material conventional borrowing in the balance sheet presented.
- Financing activities provided $18.51 million, including $16.91 million net proceeds from stock and warrant sales and $1.62 million from warrant exercises. Cash increased by $4.93 million during the year.
- Net loss was approximately 63.5% of reported revenue, a derived ratio that is not a recurring-product margin because revenue was licensing and collaboration revenue.
- Accumulated deficit was $467.45 million. The company reported no income tax expense and maintained a full valuation allowance against deferred tax assets.
Changes versus FY2025
- Revenue rose from zero, mainly reflecting BI and Altanispac licensing and collaboration arrangements.
- Net loss narrowed by approximately $8.93 million. Lower R&D expense, higher collaboration/license revenue and the absence of FY2025 comparison effects all contributed. FY2025 included a $3.13 million Vyleesi-related gain and a $2.12 million gain on purchase commitments; FY2026 recorded neither gain.
- R&D expense fell by $2.53 million, primarily from lower MC4R program spending. G&A expense increased by $1.68 million, primarily due to consulting fees.
- Operating cash use decreased by $7.77 million, but remained greater than year-end cash. Financing raised cash and the Altanispac license revenue included non-cash consideration.
- Common shares outstanding increased from 929,597 to 1,779,275 during FY2026. A 1-for-50 reverse split took effect August 8, 2025; reported share data reflects the split.
Outlook, risks and unusual items
- Going concern: Management and the auditor disclosed substantial doubt about Palatin’s ability to continue as a going concern. The company says existing cash is not expected to fund operations for at least 12 months after the financial statements were issued; without additional funding, current plans are expected to be funded only through the second half of calendar 2026. There are no committed additional financing sources. Failure to raise capital could force program reductions, suspension of trials or cessation of operations.
- Development plans: Palatin plans a Phase 1 study of its once-weekly MC4R peptide in the first half of calendar 2027, and plans to select an oral MC4R candidate for IND-enabling work in the first half of 2027, with a Phase 1 study projected for the second half of 2027. These plans depend on funding and development progress.
- Partnered programs: BI is responsible for the licensed retinal-disease program; the agreement provides for up to €280 million in contingent development, regulatory and commercial milestones plus tiered royalties, if products are commercialized. Altanispac is responsible for future development and commercialization of PL9643 for dry eye disease. Future milestones and royalties are uncertain and outside Palatin’s control.
- Other programs: Palatin reported positive topline Phase 2 results for oral PL8177 in ulcerative colitis and for an MC1R agonist in diabetic nephropathy, and positive Phase 2 results for bremelanotide combined with tirzepatide. It does not currently plan to independently fund further development of these programs and is seeking partners or other strategic opportunities.
- Key risks: Early-stage candidates may fail or be delayed; competitors include approved and investigational therapies, including Rhythm Pharmaceuticals’ MC4R products and GLP-1-based obesity therapies. Other risks include financing needs, reliance on third parties, manufacturing and clinical-trial execution, reimbursement, intellectual-property protection, dilution and Nasdaq listing compliance.
- Capital structure and listing: As of September 25, 2026, 1,780,939 common shares were outstanding and 8,763,962 shares were reported as underlying preferred stock, options, restricted stock units and warrants. Many warrants have conditional or variable exercise/termination terms. The company transferred its listing to Nasdaq Capital Market in May 2026 after prior NYSE American delisting and OTC trading.
- Other items: A dispute with H.C. Wainwright was settled in November 2025 for $500,000 cash, 10,000 warrants and repricing of existing warrants. The auditor issued an unmodified opinion on the financial statements with a going-concern explanatory paragraph. Management reported effective disclosure controls and internal control over financial reporting; no material cybersecurity incident was identified in the prior two fiscal years.
Important facts for investors to verify
- Current cash runway, cash burn and access to financing after the filing date; assess dilution and the possibility of curtailing development.
- How much of FY2026 BI revenue reflects license/milestone recognition versus reimbursed research services, and whether future partner payments are achieved.
- Altanispac’s financial and development progress on PL9643, including the expected MELODY-2 and MELODY-3 studies.
- Whether the MC4R programs meet stated candidate-selection, IND and Phase 1 timelines, and what funding those steps require.
- The potential dilution and market impact of outstanding pre-funded warrants, Series J/K warrants, preferred securities, options and restricted stock units; verify share counts and warrant terms against current filings.
- Continued compliance with Nasdaq listing requirements and the status of any subsequent financing or strategic transactions.